C.B. Dollaway Suspended 2 Years After Testing Positive for Multiple Banned Substances

By Tristen Critchfield Aug 26, 2019


Twenty-time UFC veteran C.B. Dollaway has been hit with a two-year USADA suspension after testing positive for multiple banned substances.

The anti-doping organization announced the sanction on Monday. Despite multiple infractions, Dollaway’s case is being treated as a single violation. The USADA statement is as follows:

Dollaway, 35, tested positive for anastrozole, growth hormone releasing peptide 2 (GHRP-2 or pralmorelin), a metabolite of GHRP-2, and GHRP-6 as the result of an out-of-competition urine sample he provided on December 19, 2018. Anastrozole is a Specified Substance in the class of Hormone and Metabolic Modulators, while GHRP-2 and GHRP-6 are Specified Substances in the class of Peptide Hormones, Growth Factors, Related Substances and Mimetics. All of these substances are prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency (WADA) Prohibited List.

Dollaway also tested positive for clomiphene in an out-of-competition urine sample collected on February 9, 2019. Clomiphene is a Specified Substance in the category of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy.

Additionally, Dollaway received an over-the-limit intravenous (IV) infusion on December 13, 2018. IV infusions and/or injections of more than 100 mL per 12-hour period are prohibited, except for those legitimately received in the course of hospital treatments, surgical procedures, or clinical diagnostic investigations.

Dollaway’s two positive tests and use of an over-the-limit IV were treated as a single, first violation because, after a thorough investigation, it was determined that the positive tests were consistent with ingestion prior to January 11, 2019, the date he received notification of his first positive test. Dollaway’s two-year period of ineligibility began on December 13, 2018.


Dollaway last appeared at UFC Fight Night 136 in Moscow on Sept. 15, 2018, when he suffered a second-round TKO defeat to Khalid Murtazaliev. That halted a two-bout winning streak for the Power MMA team representative, who was coming off back-to-back wins over Hector Lombard and Ed Herman. “The Doberman” is 11-9 over the course of his Octagon tenure.

Dollaway released a statement on his failed tests via Instagram.

In light of the recent decision made by USADA to issue me a two year sanction, I want it to be very clear that I did not knowingly nor intentionally take any performance enhancing drugs,” Dollaway wrote. “As many people close to me are aware, I suffered a serious back injury in 2016. With my insurance capped out, I needed to find alternative solution if I wanted to continue to compete in mixed martial arts.

“I traveled to Mexico to have a stem cell procedure done and ended up coming into contact with the mentioned substances. I am sorry to let my friends, family and fans down. I want to personally thank Donna Marcolini, the VP of health and performance of the UFC, for her assistance and for believing in me. I will take this time to continue working on my health and hopefully be ready to come back in 2020 as a healthy athlete/fighter for the first time since 2016.”

Dollaway injured his back in an elevator accident prior to UFC 203 in September 2016. As a result of the injuries suffered during that incident, his fight against Francimar Barroso was canceled.

View this post on Instagram

A post shared by CB Dollaway (@cbdollaway) on Aug 26, 2019 at 11:44am PDT

Comments

Comments powered by Disqus
<h2>Fight Finder</h2>